Krystal Biotech, Inc. (KRYS) 股票分析

公司概述

Krystal Biotech, Inc. operates as a commercial-stage biotechnology entity dedicated to discovering, developing, manufacturing, and commercializing genetic medicines designed to address diseases with high unmet medical needs within the United States. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, positioning itself to capitalize on opportunities in rare disease therapeutics and specialized genetic interventions. Krystal Biotech maintains a significant enterprise scale, evidenced by a market capitalization of $7.60 billion, trailing twelve-month revenue of $389.13 million, and a workforce comprising 295 employees. These valuation and revenue figures indicate that the market assigns substantial worth to the company's proprietary pipeline, suggesting a leading position in its niche therapeutic areas where the commercialization of VYJUVEK serves as a primary revenue driver.

财务健康

Krystal Biotech reported annual revenue of $389.13 million and net income of $204.83 million over the trailing twelve-month period, with an EBITDA of $162.92 million. The substantial gap between total revenue and net income reveals a highly efficient cost structure where the company retains over 50% of every dollar earned as profit, indicative of low variable costs relative to sales volume. The company generated free cash flow of $93.93 million, which provides considerable financial flexibility to fund research and development initiatives or pursue strategic acquisitions without immediate reliance on external capital markets. Profitability is further underscored by exceptional margins, including a gross margin of 94.1%, an operating margin of 41.3%, and a profit margin of 52.6%, all of which suggest that the business model enjoys strong pricing power and minimal cost of goods sold pressure. Balance sheet strength is highlighted by a cash position of $827.79 million compared to total debt of only $9.34 million, while the debt-to-equity ratio of 0.77 confirms a balance sheet that is conservative rather than leveraged. Liquidity is robust as indicated by a current ratio of 9.95, demonstrating that the company holds nearly ten times more current assets than current liabilities, ensuring ample coverage for short-term obligations. Management effectiveness is quantified by a return on equity of 18.9% and a return on assets of 8.4%, metrics that reveal the company generates high returns on shareholder capital and utilizes its asset base efficiently to produce earnings.

估值评估

Krystal Biotech carries a trailing P/E ratio of 37.71 and a forward P/E of 24.42, where the significant difference between these two metrics implies that the market expects earnings to expand substantially in the coming years to justify the current valuation multiple. The price-to-book ratio stands at 6.18, indicating that the market values the company at more than six times its book value, which reflects a substantial premium assigned to the intangible assets and future growth potential inherent in biotechnology firms. Alternative valuation metrics such as the price-to-sales ratio of 19.54 and an EV/EBITDA of 41.33 suggest that investors are willing to pay a high multiple for sales and earnings, consistent with high-growth biopharma profiles that prioritize pipeline value over current profitability multiples. The stock has exhibited volatility within a 52-week trading range bounded by a high of $298.30 and a low of $122.80, though the current price position relative to this specific range requires calculation based on live data not provided in the facts, strictly noting the historical boundaries of $298.30 and $122.80. Risk assessment is informed by a beta of 0.54, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting a defensive characteristic relative to the typical biotechnology sector exposure.

Growth & Income

Krystal Biotech achieved a revenue growth rate of 17.5% year-over-year and an earnings growth rate of 11.6% year-over-year. The fact that earnings growth is slower than revenue growth implies that while top-line expansion is robust, net income is being impacted by factors such as increased operating expenses or one-time costs, resulting in a divergence between sales velocity and profit acceleration. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains earnings to reinvest directly into its drug development pipeline and commercial expansion strategies. This reinvestment strategy aligns with the typical lifecycle of a commercial-stage biotechnology company that prioritizes capital allocation toward future product launches over immediate income generation for investors. Overall, the company presents a growth-oriented profile characterized by double-digit revenue expansion and strong profitability, while maintaining a zero-dividend stance that channels all excess cash toward sustaining its competitive position in the genetic medicine market.